Facial WrinklesPhase 2NCT07493850
Study to Assess the Efficacy of EMC-CAP-2025A on Age-Related Skin Parameters in Healthy Individuals
A Phase 2 study testing EMC-CAP-2025A and EMC-CAP-2025B in people with Facial Wrinkles and Skin Hydration, run by Circul'Egg at 1 site in India.
Trial summary
The goal of this clinical study is to evaluate the efficacy and tolerability of EMC-CAP-2025A, an eggshell membrane-based dietary supplement, on age-related skin parameters in healthy adults. Read more about this study
- Who is it for?
- Ages 30 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Facial Wrinkles, Skin Hydration, Skin Elasticity
- What is being tested?
- EMC-CAP-2025A and EMC-CAP-2025B
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteIndia
- Study dates
- 27 Feb 2026to 26 May 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Individuals who are willing to understand and sign a written informed consent form prior to the study.
- Healthy male and female individuals aged between 30 to 55 years (both values included).
- Individuals showing symptoms of aging, with mild to moderate wrinkles in crow's feet area based on PI discretion.
- Individuals with any one of the following skin conditions along with mild to moderate wrinkles:
- Under-eye dark circles
- Hyperpigmentation spots (blemish) (post-inflammatory hyperpigmentation, acne marks, age spots, sunspots)
Show all 10Show fewer
- Dry dull skin
- Individuals willing to maintain stable dietary patterns and maintain adequate hydration every day throughout the study
- Individuals who are willing to attend all scheduled study visits at the test center and agree to refrain from applying any topical products (e.g.,moisturizers, creams, or similar treatments) 24 hours prior to each visit.
- Willingness to participate in the study and comply with the study procedures and required visits.
Who cannot join
- Individuals having an allergy to any of the components of the IP.
- Use of another investigational product within 90 days prior to the screening visit.
- Individuals with any dermatologic disorders or skin conditions that could interfere with the evaluation of proprietary supplement's effects.
- Individuals having an underlying disease or surgical or medical condition that could put them at risk in the opinion of Principal Investigator, including anyuncontrolled chronic or serious disease that would prevent participation in the study, such as cancer, AIDS, diabetes, obesity, renal impairment, psychiatricdisorder, compromised immunity, etc.
- Individuals having a history of self-reported allergies to cosmetic and/or sunscreen products.
- Individuals who have used or are unwilling to abstain from using any topical or systemic skin-treatment products or dietary supplements with claims toimprove skin hydration, firmness, anti-aging, anti-wrinkle, skin lightening, or dyschromia correction - including those containing alpha/beta/poly-hydroxyacids, salicylic acid, vitamin C, collagen, hyaluronic acid, soy, CoQ-10, chondroitin sulfate, hydroquinone, corticosteroids, tretinoin, retinoids, or anycombination thereof - within 1 month prior to screening or during the study period.
Show all 16Show fewer
- Individuals currently using oral or topical health foods, supplements, pharmaceuticals, or cosmetics that claim whitening or skin-texture improvementeffects such as but not limited to glutathione, cysteine, placenta-based extracts, Vitamins C/E/A (retinol), astaxanthin, lycopene, etc., and who cannotrefrain from using them during the study period.
- Individuals who have undergone any facial cosmetic or aesthetic procedures, including beauty injections, deep or superficial-to-mid chemical peels,dermabrasion, laser resurfacing, Thermage, tanning, cosmetic surgery, or any equivalent high-energy or anti-aging facial treatments, within 3 months priorto the screening visit.
- Individuals who had hormone replacement therapy within 3 months preceding the screening visit.
- Individuals who have used oral contraceptives or had changed contraceptive method within 3 months prior to the screening visit, or plan to modifycontraception treatment within the duration of study.
- Employees of the clinical labs or other testing firms or laboratories, as well as those of cosmetic or raw-material manufacturers of topical products ortheir suppliers.
- Individuals who are undergoing medical treatment or have a medical history of lupus, scleroderma, atopic dermatitis, acne, facial scarring, psoriasis,eczema, and other autoimmune/inflammatory scaly skin disorders.
- History of uncontrolled hypertension with systolic blood pressure more than or equal to 140 mmHg and/or diastolic blood pressure more than or equalto 90 mmHg.
- Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
- History of smoking or currently smoking and also using any form of smokeless tobacco.
- Individuals having a history of or ongoing drug or alcohol abuse.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of EMC-CAP-2025A on Age-Related Skin Parameters in Healthy Individuals
The goal of this clinical study is to evaluate the efficacy and tolerability of EMC-CAP-2025A, an eggshell membrane-based dietary supplement, on age-related skin parameters in healthy adults.
The main questions this study aims to answer are:
Read more
- Does daily supplementation with EMC-CAP-2025A improve facial wrinkles compared to placebo?
- Does EMC-CAP-2025A improve skin hydration, firmness, elasticity, texture, and overall skin quality?
- Is EMC-CAP-2025A well tolerated when taken daily for 60 days?
Researchers will compare EMC-CAP-2025A to a placebo to assess its effects on multiple skin parameters using objective instrumental assessments and participant self-evaluations.
Participants will:
- Be randomly assigned to receive either EMC-CAP-2025A or a placebo
- Take one capsule orally once daily for 60 days
- Attend scheduled study visits at baseline, Day 30, and Day 60 for instrumental skin assessments and safety evaluations
- Complete self-assessment questionnaires related to skin quality and product tolerability
- Conditions
- Facial Wrinkles, Skin Hydration, Skin Elasticity
- Being tested
- EMC-CAP-2025A, EMC-CAP-2025B
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EMC-CAP-2025ADietary supplement
EMC-CAP-2025A 300 mg per capsule Regimen: 1 capsule per day after meals Route: Oral Duration: 60 days
EMC-CAP-2025BDietary supplement
Placebo
| Study group | Role | What they receive |
|---|---|---|
| EMC-CAP-2025A | Experimental | Not described Receives: Dietary Supplement: EMC-CAP-2025A |
| EMC-CAP-2025B | Placebo comparator | Not described Receives: Dietary Supplement: EMC-CAP-2025B |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the effect of Investigational product at Day 60 in comparison to baseline and placebo on Wrinkles in the nasolabial and lateral canthal region near the eyes (crow's feet)
Wrinkles [average wrinkle length, average wrinkle area, average wrinkle volume, average wrinkle count] measurement using 3D imaging.
Instrument: Antera 3D® (Miravex Limited, Dublin, Ireland)
Measured: Day 0 to Day 60
Secondary outcomes (8)
Skin hydration at Day 30 and Day 60 in comparison to baseline and placebo as assessed by the Moisture Meter SC.
The MoistureMeter SC measures the hydration of the skin surface, the stratum corneum. The skin is an electrically layered structure. The electrical properties of its layers are related to their water content. The probe, the skin surface and the deeper skin layers form a structure, like an electrical capacitor. The measured capacitance is proportional to the water content of the surface layer of the skin. The higher the reading, the higher the moisture content.
Instrument: MoistureMeter SC Compact (Delfin Technologies, Kuopio, Finland)
Measured: Day 0, Day 30 and Day 60
Skin firmness and elasticity at Day 30 and Day 60 in comparison to baseline and placebo as assessed by Cutometer.
The Cutometer is a measuring device that helps to estimate the degree of firmness and elasticity of the skin using negative pressure, which deforms the skin mechanically.
The measuring principle is based on the suction method. Negative pressure is created in the device, and the skin is drawn into the aperture of the probe and after a defined time released again. The resistance of the skin to the negative pressure gives the skin firmness and its ability to return to its original position gives the elasticity of the skin.
Cutometric measurements are carried out on the cheeks. The following parameters will be analyzed for this study. Readings will be taken at all visits.
- Firmness (R0): Uf= First max. Amplitude, highest point of the first curve, has an implication for the firmness of the skin. This parameter represents the passive behavior of the skin to force.
- Elasticity (R7): This gives an indication of the elasticity of the skin.
Measured: Day 0, Day 30 and Day 60
Hyperpigmentation spots (blemishes, post-inflammatory hyperpigmentation, acne marks, age spots, sunspots) at Day 30 and Day 60 in comparison to baseline and placebo as assessed by 3D imaging.
Hyperpigmentation spots (blemish, post-inflammatory hyperpigmentation, acne marks, age spots, sunspots)-[mean pigmentation, mean L*] measurement using 3D imaging.
Instrument: Antera 3D® (Miravex Limited, Dublin, Ireland)
Measured: Day 0, Day 30 and Day 60
Average pore volume and porosity index at Day 30 and Day 60 in comparison to baseline and placebo as assessed by 3D imaging.
Average pore volume and porosity index measurement using 3D imaging.
The Optical 3D is a camera for image acquisition and analysis of the skin. It relies on multi-directional illumination and computer-aided reconstruction of the skin surface, illuminating the surface from different angles and using the differences between these images to reconstruct the surface in three dimensions. The skin topography and the chromophores concentration are derived from the spatial and spectral analysis of the acquired image data, obtained by illuminating the skin with light emitting diodes (LEDs) of different wavelengths (455 to 625 nm) shining from different directions. The surface reconstructed in this way is then used for quantitative skin analysis.
Instrument: Antera 3D® (Miravex Limited, Dublin, Ireland)
Measured: Day 0, Day 30 and Day 60
Skin roughness at Day 30 and Day 60 in comparison to baseline and placebo as assessed by 3D imaging.
Skin roughness measurement using 3D imaging. The Optical 3D is a camera for image acquisition and analysis of the skin. It relies on multi-directional illumination and computer-aided reconstruction of the skin surface, illuminating the surface from different angles and using the differences between these images to reconstruct the surface in three dimensions. The skin topography and the chromophores concentration are derived from the spatial and spectral analysis of the acquired image data, obtained by illuminating the skin with light emitting diodes (LEDs) of different wavelengths (455 to 625 nm) shining from different directions. The surface reconstructed in this way is then used for quantitative skin analysis.
Instrument: Antera 3D® (Miravex Limited, Dublin, Ireland)
Measured: Day 0, Day 30 and Day 60
Skin texture and roughness at Day 30 and Day 60 in comparison to baseline and placebo as assessed by the Allergan skin roughness scale.
The Allergan Skin Roughness Scale is a validated, 5-point photo-numeric scale used by clinicians to visually assess the texture of facial skin, particularly in the midface area. It grades skin roughness from 0 (smooth) to 4 (extremely coarse), using a set of images and detailed descriptors to provide objective, consistent, and reliable assessments.
Measured: Day 0, Day 30 and Day 60
Skin quality like lines and wrinkles, crow's feet, smoothness, skin hydration, moisture, skin tone, skin radiance, skin discomfort such as itching, burning, prickling, irritation, redness and pimples on skin at Day 30 and Day 60.
A subjective self-assessment questionnaire will be administered to participants to understand participant perception of efficacy of the product.
Measured: Day 0, Day 30 and Day 60
Tolerability of the Investigational Product as assessed by self-assessment questionnaire.
Self-assessment questionnaire for in-use tolerance to capture any systemic side effects.
Measured: Day 60
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2026
- Study start27 Feb 2026
- Primary completion26 May 2026 (estimated)
- Study completion26 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Facial WrinklesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Circul'Egg
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07493850
- Sponsor's protocol ID
- CL/142/1125/STU
- Other IDs
- CTRI/2026/02/102872
- Status last verified
- Mar 2026
- First submitted
- 2 Feb 2026
- Last updated
- 2 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of EMC-CAP-2025A on Age-Related Skin Parameters in Healthy Individuals
- ClinicalTrials.gov ID
- NCT07493850
- Acronym / sponsor ID
- CL/142/1125/STU
- Conditions
- Facial Wrinkles, Skin Hydration, Skin Elasticity
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Circul'EggIndustry (pharma, biotech, devices)
- Study start
- 27 Feb 2026 (actual)
- Primary completion
- 26 May 2026 (estimated)
- Study completion
- 26 May 2026 (estimated)
- First posted
- 25 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical study is to evaluate the efficacy and tolerability of EMC-CAP-2025A, an eggshell membrane-based dietary supplement, on age-related skin parameters in healthy adults.
The main questions this study aims to answer are:
- Does daily supplementation with EMC-CAP-2025A improve facial wrinkles compared to placebo?
- Does EMC-CAP-2025A improve skin hydration, firmness, elasticity, texture, and overall skin quality?
- Is EMC-CAP-2025A well tolerated when taken daily for 60 days?
Researchers will compare EMC-CAP-2025A to a placebo to assess its effects on multiple skin parameters using objective instrumental assessments and participant self-evaluations.
Participants will:
- Be randomly assigned to receive either EMC-CAP-2025A or a placebo
- Take one capsule orally once daily for 60 days
- Attend scheduled study visits at baseline, Day 30, and Day 60 for instrumental skin assessments and safety evaluations
- Complete self-assessment questionnaires related to skin quality and product tolerability
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| EMC-CAP-2025A | Experimental | Dietary Supplement: EMC-CAP-2025A |
| EMC-CAP-2025B | Placebo comparator | Dietary Supplement: EMC-CAP-2025B |
Who may qualify
- Ages
- 30 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Individuals who are willing to understand and sign a written informed consent form prior to the study.
- Healthy male and female individuals aged between 30 to 55 years (both values included).
- Individuals showing symptoms of aging, with mild to moderate wrinkles in crow's feet area based on PI discretion.
- Individuals with any one of the following skin conditions along with mild to moderate wrinkles:
- Individuals willing to maintain stable dietary patterns and maintain adequate hydration every day throughout the study
Key exclusion criteria (16 listed)
- Individuals having an allergy to any of the components of the IP.
- Use of another investigational product within 90 days prior to the screening visit.
- Individuals with any dermatologic disorders or skin conditions that could interfere with the evaluation of proprietary supplement's effects.
- Individuals having an underlying disease or surgical or medical condition that could put them at risk in the opinion of Principal Investigator, including anyuncontrolled chronic or serious disease that would prevent participation in the study, such as cancer, AIDS, diabetes, obesity, renal impairment, psychiatricdisorder, compromised immunity, etc.
- Individuals having a history of self-reported allergies to cosmetic and/or sunscreen products.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EMC-CAP-2025AEMC-CAP-2025A 300 mg per capsule Regimen: 1 capsule per day after meals Route: Oral Duration: 60 days | Dietary supplement | EMC-CAP-2025A |
| EMC-CAP-2025BPlacebo | Dietary supplement | EMC-CAP-2025B |
Primary outcome
To assess the effect of Investigational product at Day 60 in comparison to baseline and placebo on Wrinkles in the nasolabial and lateral canthal region near the eyes (crow's feet)
Time frame: Day 0 to Day 60
Wrinkles [average wrinkle length, average wrinkle area, average wrinkle volume, average wrinkle count] measurement using 3D imaging. Instrument: Antera 3D® (Miravex Limited, Dublin, Ireland)
8 secondary outcomes
Skin hydration at Day 30 and Day 60 in comparison to baseline and placebo as assessed by the Moisture Meter SC.
Time frame: Day 0, Day 30 and Day 60
Skin firmness and elasticity at Day 30 and Day 60 in comparison to baseline and placebo as assessed by Cutometer.
Time frame: Day 0, Day 30 and Day 60
Hyperpigmentation spots (blemishes, post-inflammatory hyperpigmentation, acne marks, age spots, sunspots) at Day 30 and Day 60 in comparison to baseline and placebo as assessed by 3D imaging.
Time frame: Day 0, Day 30 and Day 60
Average pore volume and porosity index at Day 30 and Day 60 in comparison to baseline and placebo as assessed by 3D imaging.
Time frame: Day 0, Day 30 and Day 60
Skin roughness at Day 30 and Day 60 in comparison to baseline and placebo as assessed by 3D imaging.
Time frame: Day 0, Day 30 and Day 60
Skin texture and roughness at Day 30 and Day 60 in comparison to baseline and placebo as assessed by the Allergan skin roughness scale.
Time frame: Day 0, Day 30 and Day 60
Skin quality like lines and wrinkles, crow's feet, smoothness, skin hydration, moisture, skin tone, skin radiance, skin discomfort such as itching, burning, prickling, irritation, redness and pimples on skin at Day 30 and Day 60.
Time frame: Day 0, Day 30 and Day 60
Tolerability of the Investigational Product as assessed by self-assessment questionnaire.
Time frame: Day 60
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2026.
Related trials for Facial Wrinkles
Active, not recruiting
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
Wrinkle, Lax Skin
Not yet recruitingPhase 2
Can TrenibotulinumtoxinE Reverse OnabotulinumtoxinA Effect in Treating Lateral Canthal Lines?
Wrinkles and Rhytides
Active, not recruiting
Clinical Study to Evaluate the Efficacy and Safety of Matrix Pro Treatment
Skin Laxity, Wrinkle
Not yet recruiting
Effects of Probiotics on Skin Health in Healthy Women
Skin Aging, Dry Skin
Not yet recruiting
Evaluation of MD60002 Device for Facial Skin Aging
Facial Wrinkles, Skin Aging
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing EMC-CAP-2025A and EMC-CAP-2025B in people with Facial Wrinkles and Skin Hydration, run by Circul'Egg at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the effect of Investigational product at Day 60 in comparison to baseline and placebo on Wrinkles in the nasolabial and lateral canthal region near the eyes (crow's feet) (time frame: Day 0 to Day 60). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026.